Buckeyes tada ARR

Agreed - marketable Apabetalone and Zen combination oncology therapies are worth multiple billions and a 1 billion buyout is far below the market values these therapies would generate - but we need another trial before we take the drug to market and it is not a slam-dunk.The chairman had a valuation report prepared last fall which has most likely been shared with insiders, Hepa in conjunction with the debenture extension, Eversana relative to their  pre commercialization activities and PP investors. Retail investors are not privy  to the valuation #. Hepa extended the debenture which is collaterlized with the IP, Eversana ponied up 10 mil, PPs keep coming thru and ORI converted its initial loan to equity - the valuation and prognosis must have merit.

my hypothetical question to you all -

would you take a $3 per sh buyout now or risk another Phase three trial - possibly 3-5 more years of 0 ROI - the lack of management communication - the uncertainty of outcome - significantly more dilution - for an uncertain $20 per share payday or bust?